GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Nascent Biotech NBIO · USD

N/A · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

At a glance

Figures in USD, from our data supplier.

FY2024

Revenue

—

FY2015FY2024

Net income

−$2.1m

FY2015FY2024

Free cash flow

−$1.2m

FY2015FY2024

Shareholders' equity

−$256,674

FY2015FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Revenue——$1.0m$750,000———$3.0m——
Gross profit———$750,000———$3.0m——
Research and development$110,975$270,529$197,406$321,938$293,709$254,006$1.2m$486,925$1.2m$1.7m
Operating income−$2.2m−$2.2m−$457,052−$1.4m−$3.4m−$1.4m−$2.2m$1.4m−$5.4m−$2.1m
Net income−$2.1m−$2.8m−$470,390−$958,767−$4.0m−$1.4m−$2.2m$1.1m−$4.1m−$2.2m
Diluted earnings per share-0.01-0.02-0.00-0.01-0.09-0.04-0.080.05-0.21-0.15

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Total assets$552,120$255,002$105,414$751,435$3,218$131,472$116,994$899,760$1.4m$937,601
Cash and short-term investments———$1,435——————
Total liabilities$808,794$1.6m$776,890$1.2m$2.9m$613,636$203,373$165,999$3.0m$3.1m
Debt———$463,892—————$60,000
Shareholders' equity−$256,674−$1.3m−$671,476−$472,505−$2.9m−$482,164−$86,379$733,761−$1.6m−$2.2m
Shares outstanding171m132m111m105m45m33m28m24m20m14m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operations−$1.2m−$1.8m$413,479−$986,784−$554,325−$711,808−$1.2m−$768,844−$170,421−$473,297
Free cash flow−$1.2m−$1.8m$413,479−$986,784−$554,325−$711,808−$1.2m−$768,844−$170,421−$473,297

Latest quarters

By quarter end

Jun 2024Mar 2024Dec 2023Sept 2023Jun 2023Mar 2023Dec 2022Sept 2022
Operating income−$375,662−$516,029−$364,422−$837,455−$511,973−$524,293−$475,026−$521,231
Net income−$377,390−$512,576−$205,406−$829,476−$540,224−$518,059−$837,320−$145,714
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.00-0.01-0.00
Total assets$227,391$552,120$641,296$1.0m$78,922$255,002$565,844$1.2m
Shareholders' equity−$514,540−$256,674$30,367−$6,410−$1.2m−$1.3m−$1.4m−$1.2m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income16.8%10.3%14.6%
Net income29.6%8.8%0.9%

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return975%-70%12%200%21%-55%-48%104%-1%438%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.